NCT05492682 2025-09-05START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of CancerValo Therapeutics OyPhase 1 Active not recruiting15 enrolled
NCT03697824 2019-10-29Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1aGlaxoSmithKlinePhase 2 Withdrawn